SEC Form 4 · accession 0000920465-18-000058
LA JOLLA PHARMACEUTICAL CO · LJPC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Rolke
Officer — Chief Scientific Officer
Period of report
Nov 15, 2018
Accepted (ET)
Nov 19, 2018 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920465
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 15, 2018 | A | 61 | $12.665 | A | 74,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $14.90 | Nov 15, 2018 | A | 61 | A | — | Nov 15, 2028 | Common Stock | 61 | 61 | D |
Explanation of responses
- F1These shares were acquired on 11/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.